A 6-Day Losing Streak Has Stryker Stock Down 16%
A six-day slide driven largely by a single-session tumble has put the stock in the spotlight, but the underlying numbers present a complicated picture for investors to weigh.
Shares of Stryker (SYK) have fallen 16.4% over the past six trading sessions, a slide that has erased about $21 billion from the company’s market value. Stryker’s market capitalization now stands at about $106 billion.
SYK Versus The S&P 500, Streak And Beyond
Here is how SYK stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | SYK | S&P 500 |
|---|---|---|
| 1D | -8.8% | -0.6% |
| 6D (Current Streak) | -16.4% | -0.5% |
| 1M (21D) | -18.5% | -1.1% |
| 3M (63D) | -8.1% | 3.6% |
| YTD 2026 | -20.9% | 12.1% |
| 2025 | -1.5% | 16.4% |
| 2024 | 21.3% | 23.3% |
| 2023 | 23.8% | 24.2% |
The data shows a premium valuation against solid operations.
The move is specific to the stock; over the same 6 trading days the S&P 500 returned -0.5%. The company’s recent performance metrics are sound, with revenue over the last twelve months growing 8.5%, just ahead of the S&P 500 median of 8.4%. Its operating margin of 21.7% also tops the index median of 18.6%.
Even after the recent slide, the stock trades at a premium valuation, with a price-to-earnings multiple of 28.4. That is above both the S&P 500 median of 23.0 and the median of 26.5 for S&P 500 Health Care stocks. For context, 9 other S&P 500 stocks are also on losing streaks of 6 days or more.
A streak is information, not an instruction.
A streak of this length focuses investor attention on a stock’s momentum, but it is not a signal to act. The disciplined response is to check the business against the price. The recent slide has pushed the stock’s one-month return to -18.5% and its trailing twelve-month return to -28.8%. Shares now trade at about $276, matching their 52-week low.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
And for anyone who would rather back the theme than one company’s story, a healthcare ETF like XLV holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.